Chronic Spontaneous Urticaria: Features of Immunopathogenesis and New Approaches to Treatment
The purpose of this work is to review current data on the pathogenetic mechanisms of the formation of chronic spontaneous urticaria and the possibility of using a new generation of Bruton tyrosine kinase blockers. Chronic spontaneous urticaria is a disease that is often difficult to treat and significantly deteriorates the patients’ life quality. Standard therapy with antihistamines and anti-IgE therapy with omalizumab in some cases does not lead to satisfactory treatment results. The results of studies conducted in recent years have made it possible to clarify the mechanisms of rash formation in this group of patients, update the patho-genetic classification and create new drugs that can affect the course of chronic spontaneous urticaria. Bruton's tyrosine kinase is one of the most significant targets for new targeted inhibitor drugs, the most promising of which today is remibrutinib. Remibrutinib, a new oral Bruton's tyrosine kinase inhibitor hav-ing an improved efficacy and safety profile compared to its predecessors; it interacts with the inactive con-formation of Bruton's tyrosine kinase providing its irreversible inhibition to achieve a highly selective and sustainable effect.
Shkodkina S.A., Afonina I.A. 2025. Chronic Spontaneous Urticaria: Features of Immunopathogenesis and New Approaches to Treatment. Challenges in Modern Medicine, 48(1): 5–14 (in Russian). DOI: 10.52575/2687-0940-2025-48-1-5-14
While nobody left any comments to this publication.
You can be first.
Agondi R.C., Argôlo P.N., Mousinho-Fernandes M., Gehlen B., Kalil J, Motta AA. 2023. Multiple Comorbidities in Patients with Long-Lasting Chronic Spontaneous Urticaria. An. Bras. Dermatol. 98(1): 93–96. doi: 10.1016/j.abd.2022.03.004.
Altrichter S., Frischbutter S., Fok J.S., Kolkhir P., Jiao Q., Skov P.S., Metz M., Church M.K., Maurer M. 2020. The Role of Eosinophils in Chronic Spontaneous Urticaria. J. Allergy Clin. Immunol. 145(6): 1510–1516. doi: 10.1016/j.jaci.2020.03.005.
Angst D., Gessier F., Janser P., Vulpetti A., Wälchli R., Beerli C., Littlewood-Evans A., Dawson J., Nuesslein-Hildesheim B., Wieczorek G., Gutmann S., Scheufler C., Hinniger A., Zimmerlin A., Funhoff E.G., Pulz R., Cenni B. 2020. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. J. Med. Chem. 63(10): 5102–5118. doi: 10.1021/acs.jmedchem.9b01916.
Asero R., Marzano A.V., Ferrucci S., Lorini M., Carbonelli V., Cugno M. 2020. Co-Occurrence of IgE and IgG Autoantibodies in Patients with Chronic Spontaneous Urticaria. Clin. Exp. Immunol. 200(3): 242–249. doi: 10.1111/cei.13428.
Bernstein J.A., Maurer M., Saini S.S. 2024. BTK Signaling-A Crucial Link in the Pathophysiology of Chronic Spontaneous Urticaria. J. Allergy Clin. Immunol. 153(5): 1229–1240. doi: 10.1016/j.jaci.2023.12.008.
Bracken S.J., Abraham S., MacLeod A.S. 2019. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol. 10: 627. doi: 10.3389/fimmu.2019.00627.
Calzari P., Chiei Gallo A., Barei F., Bono E., Cugno M., Marzano A.V., Ferrucci S.M. 2024. Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience. J. Clin. Med. 13(18): 5610. doi: 10.3390/jcm13185610.
Çildağ S., Yenisey Ç., Ünübol M., Şentürk T. 2021. Comparison of Immunoglobulin E Anti-Thyroid Peroxidase Antibodies in Patients with Hashimoto Thyroiditis and Chronic Spontaneous Urticaria. Med. Pharm. Rep. 94(1): 53–57. doi: 10.15386/mpr-1598.
Fricke J., Ávila G., Keller T., Weller K., Lau S., Maurer M., Zuberbier T., Keil T. 2020. Prevalence of Chronic Urticaria in Children and Adults Across the Globe: Systematic Review with Meta-Analysis. Allergy. 75(2): 423–432. doi: 10.1111/all.14037.
Ghazanfar M.N., Kibsgaard L., Thomsen S.F., 2020. Vestergaard C. Risk of Comorbidities in Patients Diagnosed with Chronic Urticaria: A Nationwide Registry Study. World Allergy Organization Journal. 13: 100097. doi: 10.1016/j.waojou.2019.100097.
Giménez-Arnau A.M., Salman A. 2020. Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress. Drugs. 80(16): 1617–1634. doi: 10.1007/s40265-020-01387-9.
Gimeno R., Ribas-Llauradó C., Pesque D., Andrades E., Cenni B., Ambros B., Pujol R., Giménez-Arnau A.M. 2023. Remibrutinib Inhibits Hives Effector Cells Stimulated by Serum from Chronic Urticaria Patients Independently of FcεR1 Expression Level and Omalizumab Clinical Response. Clin. Transl. Allergy. 13(3):e12227. doi: 10.1002/clt2.12227.
Gruber B.L., Baeza M.L., Marchese M.J., Agnello V., Kaplan A.P. 1988. Prevalence and Functional Role of Anti-IgE Autoantibodies in Urticarial Syndromes. J. Invest Dermatol. 90(2): 213–7. doi: 10.1111/1523-1747.ep12462239.
Kaplan A., Lebwohl M., Giménez-Arnau A.M., Hide M., Armstrong A.W., Maurer M. 2023. Chronic Spontaneous Urticaria: Focus on Pathophysiology to Unlock Treatment Advances. Allergy. 78(2): 389–401. doi: 10.1111/all.15603.
Kaul M., End P., Cabanski M., Schuhler C., Jakab A., Kistowska M., Kinhikar A., Maiolica A., Sinn A., Fuhr R., Cenni B. 2021. Remibrutinib (LOU064): A Selective Potent Oral BTK Inhibitor with Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial. Clin. Transl. Sci. 14(5): 1756–1768. doi: 10.1111/cts.13005.
Khan D.A., Kocatürk E., Bauer A., Aygören-Pürsün E. 2021. What's New in the Treatment of Urticaria and Angioedema. J. Allergy Clin. Immunol. Pract. 9(6): 2170–2184. doi: 10.1016/j.jaip.2021.03.012.
Kim B.R., Yang S., Choi J.W. 2018. Epidemiology and Comorbidities of Patients with Chronic Urticaria in Korea: A Nationwide Population-Based Study. J. Dermatol (Tokyo) 45: 10–16. doi: 10.1111/1346-8138.14075.
Kolkhir P., Muñoz M., Asero R., Ferrer M., Kocatürk E., Metz M., Xiang Y.K., Maurer M. 2022 Autoimmune Chronic Spontaneous Urticaria. J. Allergy Clin. Immunol. 149(6): 1819–1831. doi: 10.1016/j.jaci.2022.04.010.
Kolkhir P., Borzova E., Grattan C., Asero R., Pogorelov D., Maurer M. 2017. Autoimmune Comorbidity in Chronic Spontaneous Urticaria: A Systematic Review. Autoimmun Rev. 16(12): 1196–1208. doi: 10.1016/j.autrev.2017.10.003.
Kolkhir P., Church M.K., Altrichter S., Skov P.S., Hawro T., Frischbutter S., Metz M., Maurer M. 2020. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. J. Allergy Clin. Immunol. Pract. 8(1): 318–325.e5. doi: 10.1016/j.jaip.2019.08.025.
Kolkhir P., Elieh-Ali-Komi D., Metz M., Siebenhaar F., 2022. Maurer M. Understanding Human Mast Cells: Lesson from Therapies for Allergic and Non-Allergic Diseases. Nat. Rev. Immunol. 22(5): 294–308. doi: 10.1038/s41577-021-00622-y.
Kolkhir P., Giménez-Arnau A.M., Kulthanan K., Peter J., Metz M., Maurer M. Urticaria. 2022. Nat Rev Dis Primers. 8(1): 61. doi: 10.1038/s41572-022-00389-z.
Marcelino J., Baumann K., Skov P.S., Pereira Santos M.C., Wyroslak I., Scheffel J., Altrichter S., Woetmann A., Pereira-Barbosa M., Costa C., Maurer M. 2021. What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study. Front Immunol. 12: 742470. doi: 10.3389/fimmu.2021.742470.
Мaurer M., Abuzakouk M., Bérard F., Canonica W., Oude Elberink H., Giménez-Arnau A., Grattan C., Hollis K., Knulst A., Lacour J.P., Lynde C., Marsland A., McBride D., Nakonechna A., Ortiz de Frutos J., Proctor C., Sussman G., Sweeney C., Tian H., Weller K., Wolin D., Balp M.M. 2017. The Burden of Chronic Spontaneous Urticaria is Substantial: Real-World Evidence from ASSURE-CSU. Allergy.72(12): 2005–2016. doi: 10.1111/all.13209.
Maurer M., Berger W., Giménez-Arnau A., Hayama K., Jain V., Reich A., Haemmerle S., Lheritier K., Walsh P., Xia S., Storim J. 2022. Remibrutinib, a Novel BTK Inhibitor, Demonstrates Promising Efficacy and Safety in Chronic Spontaneous Urticaria. J. Allergy Clin. Immunol. 150(6): 1498–1506. e2. doi: 10.1016/j.jaci.2022.08.027.
Maurer M., Costa C., Gimenez Arnau A., Guillet G., Labrador-Horrillo M., Lapeere H., Meshkova R., Savic S., Chapman-Rothe N. 2020. Antihistamine-Resistant Chronic Spontaneous Urticaria Remains Undertreated: 2-Year Data from the AWARE Study. Clin. Exp. Allergy. 2020 Oct; 50(10): 1166–1175. doi: 10.1111/cea.13716. Epub 2020 Sep 3.
Mendelson M.H., Bernstein J.A., Gabriel S., Balp M..M, Tian H., Vietri J., Lebwohl M. 2017. Patient-Reported Impact of Chronic Urticaria Compared with Psoriasis in the United States. J. Dermatolog. Treat. 28(3): 229–236. doi: 10.1080/09546634.2016.1227421.
Mendes-Bastos P., Brasileiro A., Kolkhir P., Frischbutter S., Scheffel J., Moñino-Romero S., Maurer M. 2022. Bruton's Tyrosine Kinase Inhibition-An Emerging Therapeutic Strategy in Immune-Mediated Dermatological Conditions. Allergy. 77(8): 2355–2366. doi: 10.1111/all.15261.
Metz M., Sussman G., Gagnon R., Staubach P., Tanus T., Yang W.H., Lim J.J., Clarke H.J., Galanter J., Chinn L.W., Chu T., Teterina A., Burgess T., Haddon D.J., Lu T.T., Maurer M. 2021. Fenebrutinib in H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Randomized Phase 2 Trial. Nat. Med. 27(11): 1961–1969. doi: 10.1038/s41591-021-01537-w.
Orzan O.A., Popa L.G., Mihai M.M., Cojocaru A., Giurcăneanu C., Dorobanțu A.M. 2022. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies. Medicina (Kaunas). 58(6): 816. doi: 10.3390/medicina58060816.
Sánchez J., Sánchez A., Cardona R. 2019. Causal Relationship Between Anti-TPO IgE and Chronic Urticaria by In Vitro and In Vivo Tests. Allergy Asthma Immunol. Res. 11(1): 29–42. doi: 10.4168/aair.2019.11.1.29.
Sánchez J., Sánchez A., Munera M., Garcia E., Lopez J.F., Velásquez-Lopera M., Cardona R. 2021. Presence of IgE Autoantibodies Against Eosinophil Peroxidase and Eosinophil Cationic Protein in Severe Chronic Spontaneous Urticaria and Atopic Dermatitis. Allergy Asthma Immunol Res. 13(5): 746–761. doi: 10.4168/aair.2021.13.5.746.
Sánchez-Borges M., Ansotegui I.J., Baiardini I., Bernstein J., Canonica G.W., Ebisawa M., Gomez M., Gonzalez-Diaz S.N., Martin B., Morais-Almeida M., Ortega Martell J.A. 2021. The Challenges of Chronic Urticaria Part 1: Epidemiology, Immunopathogenesis, Comorbidities, Quality of life, and Management. World Allergy Organ J. 14(6): 100533. doi: 10.1016/j.waojou.2021.100533.
Schmetzer O., Lakin E., Topal F.A., Preusse P., Freier D., Church M.K., Maurer M. 2018. IL-24 is a Common and Specific Autoantigen of IgE in Patients with Chronic Spontaneous Urticaria. J Allergy Clin Immunol. 142(3): 876–882. doi: 10.1016/j.jaci.2017.10.035.
Schoepke N., Asero R., Ellrich A., Ferrer M., Gimenez-Arnau A., E H Grattan C., Jakob T., Konstantinou G.N., Raap U., Skov P.S., Staubach P., Kromminga A., Zhang K., Bindslev-Jensen C., Daschner A., Kinaciyan T., Knol E.F., Makris M., Marrouche N., Schmid-Grendelmeier P., Sussman G., Toubi E., Church M.K., Maurer M. 2019. Biomarkers and Clinical Characteristics of Autoimmune Chronic Spontaneous Urticaria: Results of the PURIST Study. Allergy. 74(12): 2427–2436. doi: 10.1111/all.13949.
Thomsen S.F., Pritzier E.C., Anderson C.D. 2017 Chronic Urticaria in the Real-Life Clinical Practice Setting in Sweden, Norway and Denmark: Baseline Results from the Non-Interventional Multicentre AWARE Study. J Eur Acad Dermatol Venereol. 31: 1048–1055. doi: 10.1111/jdv.14210.
Toubi E., Vadasz Z. 2021 Predictive Features Associated with Chronic Spontaneous Urticaria Recurrence. J Dermatol. 48(11): 1786–1788. doi: 10.1111/1346-8138.16119.
Weber A.N.R., Bittner Z., Liu X., Dang T.M., Radsak M.P., Brunner C. 2017 Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Front Immunol. 8: 1454. doi: 10.3389/fimmu.2017.01454.
Zuberbier T., Abdul Latiff A.H., Abuzakouk M., Aquilina S., Asero R., Baker D., Ballmer-Weber B., Bangert C., Ben-Shoshan M., Bernstein J.A., Bindslev-Jensen C., Brockow K., Brzoza Z., Chong Neto H.J., Church M.K., Criado P.R., Danilycheva I.V., Dressler C., Ensina L.F., Fonacier L., Gaskins M., Gáspár K., Gelincik A., Giménez-Arnau A., Godse K., Gonçalo M., Grattan C., Grosber M., Hamelmann E., Hébert J., Hide M., Kaplan A., Kapp A., Kessel A., Kocatürk E., Kulthanan K., Larenas-Linnemann D., Lauerma A., Leslie T.A., Magerl M., Makris M., Meshkova R.Y., Metz M., Micallef D., Mortz C.G., Nast A., Oude-Elberink H., Pawankar R., Pigatto P.D., Ratti Sisa H., Rojo Gutiérrez M.I., Saini S.S., Schmid-Grendelmeier P., Sekerel B.E., Siebenhaar F., Siiskonen H., Soria A., Staubach-Renz P., Stingeni L., Sussman G., Szegedi A., Thomsen S.F., Vadasz Z., Vestergaard C., Wedi B., Zhao Z., Maurer M. 2022 The International EAACI/GA²LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria. Allergy. 77(3): 734–766. doi: 10.1111/all.15090.